Dave Moore ( Novo Nordisk EVP US Operations) News Coverage: NBC News, NPR, CNN, CNBC, ABC News, Scientific American, AARP, Reuters reporting on FDA approval and industry analysis Company Disclosures: MEDVi official website for platform terms and disclosures
GLP-1 agonists (semaglutide, tirzepatide) modulate insulin and glucagon secretion
Myth: Keratosis pilaris is caused by not washing your skin enough
Why is metformin usually the first medication tried
Schedule your consultation with Zen ReGen in Sacramento, CA, to see if Botox or Dysport injections are right for you
In summary, rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes